The Filings Report

Revolution Medicines, Inc. Common Stock

RVMDNasdaqCIK 1628171Healthcare / Biotechnologyfiscal year ends December30 quarters since 2019

Revenue, Q2 FY2026
—
no year-earlier figure
Net income
−$644M
−160.1% on Q2 FY2025
Free cash flow
−$390M
−70.0% on Q2 FY2025
Diluted EPS
$-3.06
−133.6% on Q2 FY2025
Revenue, TTM
—
trailing four quarters
Net margin, TTM
—
net income −$1.8B
Free cash flow, TTM
−$1.2B
−$1.2B less $9M capex
Cash and equivalents
$815M
long-term debt —, Jun 30, 2026
Shares, 12-month change
+14.7%
214M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$41.0B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Revolution Medicines, Inc. Common Stock reported no revenue line, and net loss of $644M (−160.1%). Free cash flow, operating cash flow less capital expenditures, was −$390M (−$387M less $2M). Diluted earnings per share were $-3.06.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
−$800M−$600M−$400M−$200M$0$200MQ3'22, Revenue: $3MQ3'22, Net income: −$73MQ3'22Q4'22, Revenue: $15MQ4'22, Net income: −$57MQ4'22Q1'23, Revenue: $7MQ1'23, Net income: −$68MQ1'23Q2'23, Revenue: $4MQ2'23, Net income: −$98MQ2'23Q3'23, Revenue: $0Q3'23, Net income: −$108MQ3'23Q4'23, Revenue: $742KQ4'23, Net income: −$162MQ4'23Q1'24, Revenue: $0Q1'24, Net income: −$116MQ1'24Q2'24, Revenue: $0Q2'24, Net income: −$133MQ2'24Q3'24, Revenue: $0Q3'24, Net income: −$156MQ3'24Q4'24, Revenue: $0Q4'24, Net income: −$195MQ4'24Q1'25, Net income: −$213MQ1'25Q2'25, Net income: −$248MQ2'25Q3'25, Net income: −$305MQ3'25Q4'25, Net income: −$365MQ4'25Q1'26, Net income: −$454MQ1'26Q2'26, Net income: −$644MQ2'26−$800M−$600M−$400M−$200M$0$200MQ3'22, Revenue: $3MQ3'22, Net income: −$73MQ4'22, Revenue: $15MQ4'22, Net income: −$57MQ4'22Q1'23, Revenue: $7MQ1'23, Net income: −$68MQ2'23, Revenue: $4MQ2'23, Net income: −$98MQ2'23Q3'23, Revenue: $0Q3'23, Net income: −$108MQ4'23, Revenue: $742KQ4'23, Net income: −$162MQ4'23Q1'24, Revenue: $0Q1'24, Net income: −$116MQ2'24, Revenue: $0Q2'24, Net income: −$133MQ2'24Q3'24, Revenue: $0Q3'24, Net income: −$156MQ4'24, Revenue: $0Q4'24, Net income: −$195MQ4'24Q1'25, Net income: −$213MQ2'25, Net income: −$248MQ2'25Q3'25, Net income: −$305MQ4'25, Net income: −$365MQ4'25Q1'26, Net income: −$454MQ2'26, Net income: −$644MQ2'26

Net income losses drawn in red.

Free cash flow
−$400M−$300M−$200M−$100M$0$100MQ3'22, Free cash flow: −$55MQ3'22Q4'22, Free cash flow: −$65MQ4'22Q1'23, Free cash flow: −$64MQ1'23Q2'23, Free cash flow: −$68MQ2'23Q3'23, Free cash flow: −$103MQ3'23Q4'23, Free cash flow: −$123MQ4'23Q1'24, Free cash flow: −$164MQ1'24Q2'24, Free cash flow: −$131MQ2'24Q3'24, Free cash flow: −$134MQ3'24Q4'24, Free cash flow: −$140MQ4'24Q1'25, Free cash flow: −$198MQ1'25Q2'25, Free cash flow: −$229MQ2'25Q3'25, Free cash flow: −$211MQ3'25Q4'25, Free cash flow: −$276MQ4'25Q1'26, Free cash flow: −$356MQ1'26Q2'26, Free cash flow: −$390MQ2'26−$400M−$300M−$200M−$100M$0$100MQ3'22, Free cash flow: −$55MQ4'22, Free cash flow: −$65MQ4'22Q1'23, Free cash flow: −$64MQ2'23, Free cash flow: −$68MQ2'23Q3'23, Free cash flow: −$103MQ4'23, Free cash flow: −$123MQ4'23Q1'24, Free cash flow: −$164MQ2'24, Free cash flow: −$131MQ2'24Q3'24, Free cash flow: −$134MQ4'24, Free cash flow: −$140MQ4'24Q1'25, Free cash flow: −$198MQ2'25, Free cash flow: −$229MQ2'25Q3'25, Free cash flow: −$211MQ4'25, Free cash flow: −$276MQ4'25Q1'26, Free cash flow: −$356MQ2'26, Free cash flow: −$390MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$250M$500M$750M$1.0BQ3'22, Cash and equivalents: $179MQ3'22Q4'22, Cash and equivalents: $161MQ4'22Q1'23, Cash and equivalents: $427MQ1'23Q2'23, Cash and equivalents: $380MQ2'23Q3'23, Cash and equivalents: $358MQ3'23Q4'23, Cash and equivalents: $696MQ4'23Q1'24, Cash and equivalents: $288MQ1'24Q2'24, Cash and equivalents: $276MQ2'24Q3'24, Cash and equivalents: $201MQ3'24Q4'24, Cash and equivalents: $543MQ4'24Q1'25, Cash and equivalents: $334MQ1'25Q2'25, Cash and equivalents: $402MQ2'25Q3'25, Cash and equivalents: $217MQ3'25Q4'25, Cash and equivalents: $384MQ4'25Q1'26, Cash and equivalents: $441MQ1'26Q2'26, Cash and equivalents: $815MQ2'26$0$250M$500M$750M$1.0BQ3'22, Cash and equivalents: $179MQ4'22, Cash and equivalents: $161MQ4'22Q1'23, Cash and equivalents: $427MQ2'23, Cash and equivalents: $380MQ2'23Q3'23, Cash and equivalents: $358MQ4'23, Cash and equivalents: $696MQ4'23Q1'24, Cash and equivalents: $288MQ2'24, Cash and equivalents: $276MQ2'24Q3'24, Cash and equivalents: $201MQ4'24, Cash and equivalents: $543MQ4'24Q1'25, Cash and equivalents: $334MQ2'25, Cash and equivalents: $402MQ2'25Q3'25, Cash and equivalents: $217MQ4'25, Cash and equivalents: $384MQ4'25Q1'26, Cash and equivalents: $441MQ2'26, Cash and equivalents: $815MQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Revolution Medicines, Inc. Common Stock income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue——————00—
Cost of revenue—————————
Gross profit—————————
Research and development395344295263224206188152+76.2%
Selling, general and administrative110101675341352824+171.6%
Operating income(505)(445)(362)(315)(265)(241)(216)(176)−90.8%
Other income (expense)(139)(9)(3)1017272119−922.6%
Pretax income(644)(454)(365)(305)(248)(213)(195)(156)−160.1%
Income tax——————(1)0—
Net income(644)(454)(365)(305)(248)(213)(195)(156)−160.1%
Diluted EPS ($)(3.06)(2.29)—(1.61)(1.31)(1.13)—(0.94)−133.6%
Diluted shares (millions)211198—189189188—167—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Revolution Medicines, Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents815441384217402334543201+102.6%
Short-term investments3,1231,4671,6421,7141,7351,7691,7461,348+80.0%
Total current assets4,0281,9682,0751,9772,1762,1352,3281,579+85.1%
Total assets4,3232,2542,3552,2522,4302,3652,5581,763+77.9%
Total current liabilities354290290246185159164111+91.9%
Long-term debt—————————
Total liabilities1,717754723655564287293197+204.3%
Stockholders’ equity2,6061,5001,6311,5971,8652,0782,2651,566+39.7%
Shares outstanding (millions)214213198193187186186168—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Revolution Medicines, Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow(387)(354)(274)(207)(222)(194)(138)(130)−74.7%
Capital expenditures22237314−69.3%
Free cash flow (CFO − capex)(390)(356)(276)(211)(229)(198)(140)(134)−70.0%
Depreciation and amortization22222222+6.8%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 25, 2026.

Income statement

Revolution Medicines, Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 2, 2021FY2019ended Dec 31, 2019filed May 14, 2020FY2018ended Dec 31, 2018filed May 14, 2020
Revenue00123529435020
Cost of revenue————————
Gross profit————————
Research and development9875924232531871329251
Selling, general and administrative1959776413021129
Operating income(1,182)(690)(487)(258)(188)(111)(54)(40)
Other income (expense)5189479122(1)
Pretax income(1,131)(601)(440)(249)(187)(109)(52)(42)
Income tax0(1)(4)000(4)—
Net income(1,131)(600)(436)(249)(187)(108)(48)(42)
Diluted EPS ($)(5.95)(3.58)(3.86)(3.08)(2.57)(2.01)——
Diluted shares (millions)190168113817355——

Balance sheet

Revolution Medicines, Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 2, 2021FY2019ended Dec 31, 2019filed May 14, 2020FY2018ended Dec 31, 2018filed May 14, 2020
Cash and equivalents3845436961611081041770
Short-term investments1,6421,7461,157484469336106—
Total current assets2,0752,3281,879660590454134—
Total assets2,3552,5582,062812738567221—
Total current liabilities29016414462604743—
Long-term debt————————
Total liabilities7232932361271359368—
Stockholders’ equity1,6312,2651,826685603475(153)(108)
Shares outstanding (millions)198186165907473——

Cash flow statement

Revolution Medicines, Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 2, 2021FY2019ended Dec 31, 2019filed May 14, 2020FY2018ended Dec 31, 2018filed May 14, 2020
Operating cash flow(898)(557)(351)(224)(147)(100)(50)1
Capital expenditures16108117331
Free cash flow (CFO − capex)(914)(568)(358)(235)(154)(103)(52)0
Depreciation and amortization87543322
Share repurchases————————
Dividends paid—————0——

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$78M
80 sales by 9 insiders; officers and directors $78M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$154M
158 sales by 12 insiders; officers and directors $154M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 26, 2026Mancini AnthonySee Remarksoption exercise2,310$33.62$78K42,075Oct 28, 2026
Oct 26, 2026Mancini AnthonySee Remarksopen-market sale10b5-12,310$186.99$432K39,765Oct 28, 2026
Sep 29, 2026Sandler Alan B.Chief Development Officeroption exercise6,000$58.84$353K58,868Oct 1, 2026
Sep 29, 2026Sandler Alan B.Chief Development Officeropen-market sale10b5-12,200$200.82$442K56,668Oct 1, 2026
Sep 29, 2026Sandler Alan B.Chief Development Officeropen-market sale10b5-11,609$201.72$325K55,059Oct 1, 2026
Sep 29, 2026Sandler Alan B.Chief Development Officeropen-market sale10b5-11,000$202.81$203K54,059Oct 1, 2026
Sep 29, 2026Sandler Alan B.Chief Development Officeropen-market sale10b5-11,199$203.91$244K52,860Oct 1, 2026
Sep 29, 2026Sandler Alan B.Chief Development Officeropen-market sale10b5-1301$204.72$62K52,559Oct 1, 2026
Sep 25, 2026Cislini JeffSVP & General Counselopen-market sale10b5-1765$207.32$159K51,776Sep 29, 2026
Sep 25, 2026Mancini AnthonySee Remarksoption exercise3,121$33.62$105K42,886Sep 28, 2026
Sep 25, 2026Mancini AnthonySee Remarksopen-market sale10b5-13,121$200.54$626K39,765Sep 28, 2026
Sep 24, 2026Mancini AnthonySee Remarksopen-market sale10b5-1587$200.00$117K39,765Sep 28, 2026
Sep 22, 2026Anderson Elizabeth MDirectoroption exercise5,070$1.12$6K14,476Sep 24, 2026
Sep 22, 2026Anderson Elizabeth MDirectoropen-market sale10b5-1910$191.85$175K13,566Sep 24, 2026
Sep 22, 2026Anderson Elizabeth MDirectoropen-market sale10b5-14,985$192.54$960K8,581Sep 24, 2026
Sep 22, 2026Anderson Elizabeth MDirectoropen-market sale10b5-12,648$193.44$512K5,933Sep 24, 2026
Sep 22, 2026Anderson Elizabeth MDirectoropen-market sale10b5-11,500$194.59$292K4,433Sep 24, 2026
Sep 22, 2026Anderson Elizabeth MDirectoropen-market sale10b5-1100$195.15$20K4,333Sep 24, 2026
Sep 18, 2026Mancini AnthonySee Remarksopen-market sale10b5-11,764$196.94$347K40,352Sep 22, 2026
Sep 16, 2026Sandler Alan B.Chief Development Officeropen-market sale10b5-15$194.96$97553,204Sep 18, 2026
Sep 16, 2026Sandler Alan B.Chief Development Officeropen-market sale10b5-1336$199.30$67K52,868Sep 18, 2026
Sep 16, 2026Mancini AnthonySee Remarksopen-market sale10b5-127$195.05$5K43,863Sep 18, 2026
Sep 16, 2026Mancini AnthonySee Remarksopen-market sale10b5-11,747$199.30$348K42,116Sep 18, 2026
Sep 16, 2026Kelsey Stephen MichaelSee Remarksopen-market sale10b5-185$195.01$17K291,791Sep 18, 2026
Sep 16, 2026Kelsey Stephen MichaelSee Remarksopen-market sale10b5-15,484$199.30$1M286,307Sep 18, 2026

Full insider history for Revolution Medicines, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held RVMD in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded RVMD by quarter.

FundManagerQuarterValueSharesWeightMove
Duquesne Family OfficeStanley DruckenmillerQ2 2026$75M399,5871.44%added +26.5%
Baron Capital GroupRon BaronQ2 2026$2M12,5000.00%added +400.0%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Revolution Medicines, Inc., CIK 1628171 on EDGAR
Extract generated
November 1, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: depreciation amortization FY2019
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue: not filed
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAmortizationAndAccretionNet, DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/RVMD.json